Aptitude Secures $9M Partnership with BARDA to Develop Rapid Molecular Diagnostic for Ebola viruses and Marburg Viruses

Aptitude Medical Systems (Aptitude™) announced today its second major partnership with the Biomedical Advanced Research and Development Authority (BARDA), with $9 million in funding to develop the Metrix Filovirus Panel. This rapid next-generation molecular diagnostic device aims to detect and differentiate Ebolavirus and Marburgvirus species. It is a small, portable platform, making it appropriate for use in remote and more traditional point-of-care settings, generating results in 30 minutes or less from venous or fingerstick blood samples.